1 Like
Interesting. Tropisetron shows the largest effect, according to them. It works as a partial agonist to the famous alpha-7 nicotinic receptor, which has long been one of the promising targets in schizophrenia, but I don’t remember any drug being specifically approved for use in SZ.
Some authors are members of companies - InovIntell and Assignity (Netherlands, Poland)
The eClinicalMedicine journal has an impact factor 15.1, which is quite high - I hope they do at least some perfunctory review of manuscripts.